Cargando…
Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities
We recently reported that the antitumor triazoloacridone, compound C-1305, is a topoisomerase II poison with unusual properties. In this study we characterize the DNA interactions of C-1305 in vitro, in comparison with other topoisomerase II inhibitors. Our results show that C-1305 binds to DNA by i...
Autores principales: | Lemke, Krzysztof, Wojciechowski, Marcin, Laine, William, Bailly, Christian, Colson, Pierre, Baginski, Maciej, Larsen, Annette K., Skladanowski, Andrzej |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1270948/ https://www.ncbi.nlm.nih.gov/pubmed/16254080 http://dx.doi.org/10.1093/nar/gki904 |
Ejemplares similares
-
Triazoloacridone C-1305 impairs XBP1 splicing by acting as a potential IRE1α endoribonuclease inhibitor
por: Bartoszewska, Sylwia, et al.
Publicado: (2021) -
Utilizing Genome-Wide mRNA Profiling to Identify the Cytotoxic Chemotherapeutic Mechanism of Triazoloacridone C-1305 as Direct Microtubule Stabilization
por: Króliczewski, Jarosław, et al.
Publicado: (2020) -
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells()
por: Węsierska-Gądek, Józefa, et al.
Publicado: (2012) -
Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C-1305()
por: Potęga, Agnieszka, et al.
Publicado: (2020) -
Combined anticancer therapy with imidazoacridinone analogue C‐1305 and paclitaxel in human lung and colon cancer xenografts—Modulation of tumour angiogenesis
por: Świtalska, Marta, et al.
Publicado: (2022)